Welcome to our dedicated page for Zenas BioPharma news (Ticker: ZBIO), a resource for investors and traders seeking the latest updates and insights on Zenas BioPharma stock.
Zenas BioPharma, Inc. (Nasdaq: ZBIO) is a clinical-stage global biopharmaceutical company focused on autoimmune diseases, and its news flow reflects active development across multiple programs. Company announcements frequently highlight progress with its lead product candidate, obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb across the B cell lineage to inhibit cells implicated in autoimmune disease without depleting them. News items include updates on the Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease (IgG4-RD), Phase 2 MoonStone trial in Relapsing Multiple Sclerosis (RMS), and Phase 2 SunStone trial in Systemic Lupus Erythematosus (SLE), including reports of statistically significant efficacy results and safety findings.
Investors following ZBIO news can also track developments related to orelabrutinib, a late-stage, highly selective CNS-penetrant, oral BTK inhibitor licensed from InnoCare Pharma. Press releases cover Phase 3 trials in Primary Progressive Multiple Sclerosis (PPMS) and planned trials in Secondary Progressive Multiple Sclerosis (SPMS), as well as partner-reported data in SLE. Additional news covers earlier-stage programs ZB021 and ZB022, described as potentially best-in-class oral IL-17AA/AF and TYK2 inhibitors in IND-enabling or preclinical stages.
Regulatory, financing and corporate updates are another key component of Zenas BioPharma’s news. The company issues releases on revenue participation and funding agreements, such as its obexelimab funding arrangement with Royalty Pharma, private placement financings, and material license agreements with InnoCare. Earnings-related press releases and Form 8-K–linked announcements provide context on cash runway, research and development spending, and strategic priorities.
This ZBIO news page aggregates these disclosures so readers can follow clinical milestones, regulatory plans, licensing transactions and capital raises associated with Zenas’ autoimmune pipeline. For investors, analysts and healthcare professionals, it offers a single view into how obexelimab, orelabrutinib, ZB021 and ZB022 are progressing through development and how the company is structuring partnerships and funding to support its programs.
Zenas BioPharma (Nasdaq: ZBIO) announced inducement grants dated February 17, 2026, awarding newly hired employees 35,700 stock options and 53,625 RSUs. The options carry a $26.77 exercise price, a ten-year term, and multi-year vesting under the company's 2026 Inducement Plan.
Options vest 25% after one year then monthly over three years; RSUs vest in four equal annual installments on Feb 15 each year from 2027–2030.
Zenas BioPharma (Nasdaq: ZBIO) reported Phase 2 MoonStone results for obexelimab in relapsing multiple sclerosis. Obexelimab achieved a 95% relative reduction in new gadolinium-enhancing T1 lesions over weeks 8 and 12 (p=0.0009) with near-complete suppression by week 8 and durable effect through week 24.
Adjusted mean lesions per scan were 0.01 vs 0.23 for placebo; serum NfL declined 40% by week 24. Safety was consistent with prior trials and no new safety signals were observed.
Zenas BioPharma (NASDAQ: ZBIO) said management will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 1:30 p.m. ET. A live webcast and archived replay will be available under Events and Presentations in the Investor & Media Relations section of the company website.
Zenas BioPharma (Nasdaq: ZBIO) announced an inducement grant under Nasdaq Listing Rule 5635(c)(4) dated Jan 15, 2026. The Compensation Committee granted a non-qualified stock option to a newly hired employee to purchase 100,000 shares of common stock.
The option has a 10-year term, an exercise price of $19.93 per share (equal to the closing price on the grant date), and vests over 4 years (25% after one year, then 36 equal monthly installments), subject to continued service and the terms of the 2026 Inducement Plan and the related option agreement.
Zenas BioPharma (Nasdaq: ZBIO) announced positive Phase 3 INDIGO results for obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD). Obexelimab met the primary endpoint with a 56% reduction in risk of IgG4-RD flare versus placebo (Hazard Ratio 0.44, p=0.0005) over 52 weeks and achieved statistically significant results on all four key secondary endpoints. The drug was well tolerated with no new safety signals, similar injection site reaction rates, and lower infection rates versus placebo. Zenas plans to submit a BLA to FDA in Q2 2026 and an MAA to EMA in H2 2026. Full INDIGO data will be presented at a future medical meeting and a conference call was scheduled for January 5, 2026.
Zenas BioPharma (Nasdaq: ZBIO) announced inducement option grants on December 15, 2025 to two newly hired employees totaling 300,000 non-qualified stock options. The options have a 10-year term and an exercise price of $32.59, equal to the closing price on the grant date. Vesting is over four years: 25% on the one-year anniversary of each employee's start date, then the remainder in 36 equal monthly installments, subject to continued service. Grants are governed by an Inducement Option Award Agreement and were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Zenas BioPharma (Nasdaq: ZBIO) highlighted that partner InnoCare achieved the primary endpoint in a Phase 2b study of orelabrutinib for Systemic Lupus Erythematosus (SLE) on Dec 15, 2025. In a 187‑patient, randomized (1:1:1) trial, orelabrutinib 75 mg QD produced an SRI‑4 response rate of 57.1% vs 34.4% for placebo at week 48 (p < 0.05). The 75 mg dose showed dose‑dependent benefit versus 50 mg and achieved higher SRI‑6 and BICLA response rates (p < 0.05). Orelabrutinib was reported as well tolerated. Separately, China’s CDE approved a Phase 3 registrational trial in SLE, and Zenas retains commercial/development rights for MS and certain non‑oncology territories per an Oct 2025 license.
Zenas BioPharma (Nasdaq: ZBIO) reported Q3 2025 results and a corporate update highlighting clinical progress, pipeline expansion, and financing. Key items include Phase 2 MoonStone obexelimab data in relapsing MS showing a 95% relative reduction in new GdE T1 lesions (p=0.0009), an expected topline readout from the Phase 3 INDIGO trial in IgG4-RD around year-end 2025, and a transformational license for orelabrutinib with Phase 3 programs for PPMS initiated Q3 2025 and SPMS planned Q1 2026.
Financing highlights: up to $300M from Royalty Pharma (including $75M upfront) and a $120M private placement. Cash and investments were $301.6M at Sept 30, 2025.
Zenas BioPharma (Nasdaq: ZBIO) announced management will present at two investor conferences: the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 11:00 a.m. GMT, and the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 7:55 a.m. ET.
Live webcasts and archived replays will be available under Events and Presentations in the company’s Investor & Media Relations website.
Zenas BioPharma (Nasdaq: ZBIO) announced positive Phase 2 MoonStone results for obexelimab in relapsing multiple sclerosis on October 27, 2025. Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium-enhancing T1 lesions versus placebo over weeks 8 and 12 (p=0.0009), with adjusted mean new GdE T1 lesions per scan of 0.01 vs 0.23. The drug also significantly reduced new/enlarging T2 lesions. Safety was consistent with prior trials, including infections and hypersensitivity, most commonly mild injection-site reactions. Zenas expects 24-week MoonStone data in Q1 2026 and additional toplines from INDIGO (IgG4-RD) and SunStone (SLE) in late 2025–mid 2026.